Agios Pharmaceuticals, Inc. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing also reports fourth-quarter results. Agios was a clinical-stage biopharmaceutical company developing metabolism-targeted therapies for cancer and rare genetic disorders; it had no product sales or approved products.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue | $65.4 million | $25.5 million |
| Research and development expense | $100.4 million | $54.5 million |
| General and administrative expense | $19.1 million | $9.9 million |
| Operating loss | $54.1 million | $38.9 million |
| Net loss | $53.5 million | $39.4 million |
| Net loss per share, basic and diluted | $1.59 | $2.83 |
| Net cash used in operating activities | $59.4 million | $56.4 million |
- Fourth-quarter 2014 revenue was $14.6 million, compared with $6.7 million in fourth-quarter 2013. Fourth-quarter net loss was $26.7 million, versus $12.4 million.
- Year-end cash, cash equivalents and marketable securities totaled $467.4 million, up from $193.9 million. Total assets were $491.9 million; total liabilities were $67.5 million. The filing reports no debt balance.
- Year-end stockholders’ equity was $424.4 million. Operating lease obligations totaled $50.4 million; these are contractual commitments, not reported debt.
- There was no product gross margin to report. Revenue was primarily from Celgene collaboration arrangements and was not recurring product revenue.
- Revenue rose 156%, but the increase was substantially affected by a July 2014 collaboration-agreement amendment and related revenue-recognition change. Operating expenses grew 86% overall, including an 84% increase in R&D.
Business, developments and outlook
- Lead programs were AG-221 (IDH2-mutant cancers), AG-120 (IDH1-mutant cancers) and AG-348 (pyruvate kinase deficiency). All remained investigational.
- Agios reported early clinical activity for AG-221 and AG-120, including objective responses and reductions in 2HG; these were early-stage findings, not evidence of approval or established clinical benefit. AG-348 phase 1 studies in healthy volunteers showed pharmacodynamic effects; Agios planned a phase 2 patient study in the first half of 2015.
- Celgene licensed AG-221 worldwide in 2014 and funds its development. In January 2015, Celgene agreed to license AG-120 outside the U.S., subject to required approvals; Agios retained U.S. rights and associated development responsibilities.
- Celgene extended the discovery collaboration through April 2016 for an additional $20 million, expected in the second quarter of 2015. Agios stated that year-end resources, anticipated tax refunds, interest and collaboration payments and reimbursements were expected to fund operations and capital requirements until at least late 2017.
- Management expected expenses and operating losses to increase as research and clinical programs advanced. The company cautioned that timing, costs and outcomes of development and regulatory approval were uncertain, and that additional capital might be required.
- Material risks include clinical-trial failure or delay, patient enrollment and safety issues, reliance on Celgene and other third parties, manufacturing and supply dependence, patent uncertainty and competition, reimbursement and pricing pressure, and the need for future financing. No material legal proceedings were reported.
- Revenue was unusually affected by the July 2014 Celgene amendment: Agios recognized $42.7 million through the amendment date under prior accounting and modification accounting; total 2014 collaboration revenue was $65.4 million. The third quarter was profitable because of collaboration revenue recognition, while the fourth quarter recorded a substantial loss.
Most important facts for investors to verify
- Reconcile the $65.4 million reported revenue to the Celgene amendment, recognized license consideration, ongoing services and cost reimbursements; distinguish recognized revenue from cash received.
- Track actual cash burn and spending against management’s late-2017 runway estimate, including the expected $20 million Celgene payment and reimbursable costs.
- Review subsequent clinical data, trial enrollment, safety findings and regulatory plans for AG-221, AG-120 and AG-348; early response figures were based on small, evolving trials.
- Confirm the status and final terms of Celgene’s AG-120 ex-U.S. license and the allocation of development costs, milestones and royalties.
- Assess dilution from equity financing and stock-based compensation, as well as lease commitments and the company’s dependence on third-party manufacturers and collaborators.